Articles by Alison Bryant
Most vaccines consist of an inactivated virus to train the immune system to attack an invader. But such a system poses risks patients, especially when it comes to HIV. Like many vaccine researchers, those at the Massachusetts Institute of Technology are exploring alternative DNA vaccines.
A partial dose of the polio vaccine works just as well as a full one in providing a basic level of immunity against the disease, a new study shows.
An unusually widespread flu season--complete with vaccine shortages and high demand--has scientists and vaccine makers working to develop a quickly produced and long-lasting shot. Life Technologies took a step in this direction with the establishment of the Global Influenza Network.
Analysts expect the U.S. vaccine market to rack up to $12.8 billion in sales for 2012. And Transparency Market Research says the industry can expect to see 5.3% growth through 2018. But low vaccination rates among U.S. adults may hamper that upward trend.
The FDA will now allow use of Prevnar 13 in children and adolescents ages 6 to 17, a recent expansion that could allow Pfizer to hit lofty sales goals.
Small Indian vaccine makers are starting to drum up low-cost shots for developing countries and Big Pharma wants to compete with these up-and-coming rivals. GlaxoSmithKline ($GSK) announced an agreement to team up with an Indian venture to produce a 6-in-1 vaccine to protect against polio and 5 other diseases.
The United Nations backed down from a ban on a vaccine preservative that could have driven up prices and required a complex network of cold storage facilities.
Just more than a year after putting a voluntary moratorium on certain experiments involving the H5N1 avian influenza virus, researchers say the studies should restart.
Almost half of all babies and toddlers in the United States aren't receiving vaccines on time, a new study shows.
A heightened flu season and a spate of newly approved influenza vaccines have experts wondering what else they can do to mitigate or prevent the seasonal illness. Next up: A universal flu vaccine administered every 5 to 10 years to fight multiple virus strains and eradicate the need for annual shots.